Skip to content

Study · Non-randomized trial · 1995

4 results

A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer.

Jonat W, Kaufmann M, Blamey RW, Howell A, Collins JP, Coates A, Eiermann W, Jänicke F, Njordenskold B, Forbes JF

European journal of cancer (Oxford, England : 1990)1 Jan 1995Cited by 57 (Europe PMC)

PMID7718316 (opens in a new tab)DOI10.1016/0959-8049(94)00415-2 (opens in a new tab)PepBankPUB-07718316
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In pre- and perimenopausal advanced breast cancer patients, goserelin alone produced objective responses in 31% at median follow-up of 93 weeks.

    In plain wordsIn patients with advanced breast cancer, 31% had objective responses with goserelin alone.

    Peptide
    Goserelin
    Outcome
    Not applicableObjective response
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Measurements

    Objective response rate
    31%
    goserelin alone, median follow-up 93 weeks

    Source sentences

    Summary
    With a median follow-up of 93 weeks, 31% of goserelin-treated patients had objective responses (UICC criteria) compared with 38% of goserelin plus tamoxifen-treated patients (P = 0.24).
    1 context sentence
    Summary · context
    The use of goserelin with or without tamoxifen was investigated in a randomised multicentre study involving 318 pre- and perimenopausal advanced breast cancer patients.
  2. 02HumanNon-randomized trialEfficacy outcome

    In advanced breast cancer patients, median time to disease progression was 23 weeks with goserelin alone.

    In plain wordsIn patients with advanced breast cancer, median time to disease progression was 23 weeks with goserelin alone.

    Peptide
    Goserelin
    Outcome
    Not applicableTime to disease progression
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Measurements

    Median time to disease progression
    23 weeks
    goserelin alone group

    Source sentences

    Summary
    Median times for disease progression and survival were 23 and 127 weeks in the goserelin alone group and 28 and 140 weeks in the combination group, respectively.
    1 context sentence
    Summary · context
    The use of goserelin with or without tamoxifen was investigated in a randomised multicentre study involving 318 pre- and perimenopausal advanced breast cancer patients.
  3. 03HumanNon-randomized trialEfficacy outcome

    In advanced breast cancer patients, median survival was 127 weeks with goserelin alone.

    In plain wordsIn patients with advanced breast cancer, median survival was 127 weeks with goserelin alone.

    Peptide
    Goserelin
    Outcome
    Not applicableSurvival
    Study

    n: not reported in source

    Outcome group
    Mortality · Cancer
    Studied dose
    Dose not stated

    Measurements

    Median survival
    127 weeks
    goserelin alone group

    Source sentences

    Summary
    Median times for disease progression and survival were 23 and 127 weeks in the goserelin alone group and 28 and 140 weeks in the combination group, respectively.
    1 context sentence
    Summary · context
    The use of goserelin with or without tamoxifen was investigated in a randomised multicentre study involving 318 pre- and perimenopausal advanced breast cancer patients.
  4. 04HumanNon-randomized trialSafety outcome

    In advanced breast cancer patients, goserelin alone was well tolerated.

    In plain wordsIn patients with advanced breast cancer, goserelin alone was well tolerated.

    Peptide
    Goserelin
    Outcome
    Not applicableTolerability
    Study

    n: not reported in source

    Outcome group
    Adverse events · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both treatments were well tolerated and no additional safety issues were associated with combination therapy.
    1 context sentence
    Summary · context
    The use of goserelin with or without tamoxifen was investigated in a randomised multicentre study involving 318 pre- and perimenopausal advanced breast cancer patients.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.